The mission of DAS is to identify, acquire and develop unique assets for conditions overlooked or under-served by current treatment approaches to improve patient outcomes.
Myasthenia gravis is a debilitating, chronic autoimmune disease of the neuromuscular junction affecting a person’s muscle strength and ability to function. Current treatment options may cause side effects that lead to significant tolerability issues. DAS-001 is a proposed fixed-dose combination tablet that combines the gold standard first-line treatment, pyridostigmine, with an antagonist of the gastrointestinal side effects of pyridostigmine.
A successful Phase 1 study was completed in healthy volunteers and we have begun Phase 2 clinical trial enrollment.
Read the press release
To learn more about DAS-MG or discuss partnership opportunities, please contact us at:
312-508-0101 or email@example.com
Raimonds has worked in a broad range of roles within healthcare for the duration of his 20+ year career. In the earlier years of his career he worked at Cooper & Lybrand (PwC) as a management consultant, followed by a few commercial roles at Eli Lilly and Company. More recently he has held senior commercial leadership roles in companies such as Collegium and Lundbeck, where Raimonds has brought a disciplined approach to strategic planning with focused execution.
Raimonds has launched numerous products across multiple therapeutic areas, including rare neurologic diseases. Additionally, Raimonds led agency teams at Palio, Saatchi & Saatchi, and TargetRx, where he closely collaborated with clients on numerous complex launches. Raimonds has worked across the US and in Europe.
He holds an MBA from Thunderbird School of Global Management and a BS in Business from the University of the Pacific.
Christina has over 20 years of research and development experience. Christina’s R&D experience has primarily focused on clinical development and medical application of pharmaceuticals, devices, and biologics.
Christina has held leadership positions with responsibilities for various R&D functions across multiple therapeutic areas, both within leading global pharmaceutical companies Johnson & Johnson, Bristol Myers Squibb, and Sanofi Genzyme, as well as in specialty pharmaceutical companies, such as Medicis and Pacira. Christina has a strong track record spanning early clinical development through to commercialization, holding key roles in bringing first in class indications and breakthrough therapies to market in the US. She also has direct and cross functional leadership experience in regulatory affairs, commercialization, and reimbursement.
Christina earned her PharmD at St. Louis College of Pharmacy and completed her residency in internal medicine with an emphasis in critical care at St. Elizabeth’s Hospital, Illinois. She completed her MBA at Lindenwood University. She has authored publications and presented at national and international congresses.
Michael has developed innovative commercial strategies and led high performing teams within healthcare, most recently as Senior Vice President, Global Accounts at Eversana. Prior to joining Eversana, he spent time with Lundbeck and Hospira developing deep expertise in global commercial operations and business development. His experience spans the full product lifecycle from leading numerous acquisitions, in-licensings, and divestitures to launching new products as both a sales and marketing leader. He has held global and regional roles supporting a broad range of therapeutic areas including neurology, oncology, and biologics.
Michael is a patient advocate and early childhood education champion with a strong record of community engagement and impact through advising and fundraising.
He holds an MBA and an MS in Finance from DePaul and a BS in Management from Purdue University.
Dr. Clarence-Smith is a neurologist whose career has been dedicated to identifying, selecting, and shepherding pharmaceuticals from early development stages onto the market. She has worked in senior positions in large pharmaceutical companies (Sanofi, Roche, Otsuka) and more recently founded and raised money to start several pharmaceutical companies.
Over 20 years of corporate finance and pharmaceutical industry experience at Credit Suisse, Novartis and CureVac where he led several transformative transactions as well as product development and launches. More recently he focused on the creation of start-up companies dedicated to the late-stage development of specialty pharmaceuticals.